Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder, accounting for approximately 5% of all ESRD cases worldwide. As a vasopressin receptor 2 antagonist, tolvaptan is the FDA-approved therapeutic agent for ADPKD, which is only made available...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Karger Publishers,
2021-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|